CytomX Therapeutics is teaming up with Astellas Pharma in a research and development alliance focused on developing new cancer immunotherapies based on its antibody technology. Under the terms of the deal announced this week, Astellas is paying CytomX $80 million up front. For its part, CytomX will conduct and finance the research up to the selection of drug candidates. Astellas will take the lead from there, funding preclinical and clinical research. Depending on the progress of those programs, Astellas could pay CytomX up to $1.6 billion more, plus royalties from sales of any approved products. Learn More